6-甲氧基-2-苯基-4(1H)-嘧啶酮 | 59081-26-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-甲氧基-2-苯基-4(1H)-嘧啶酮
• 英文名称: 6-methoxy-2-phenylpyrimidin-4-ol
• 英文别名: 4-methoxy-2-phenyl-1H-pyrimidin-6-one
• CAS: 59081-26-4
• 化学式: C₁₁H₁₀N₂O₂
• 分子量: 202.213
• InChiKey: ISNOBWDIOHJVOD-UHFFFAOYSA-N

物化性质

• 沸点：
  345.4±52.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-甲氧基-2-苯基-4(1H)-嘧啶酮 在 potassium carbonate 、 caesium carbonate 作用下， 以 丙酮 、 乙腈 为溶剂， 生成 4-methoxy-2-phenyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Sigma-1 Receptor Antagonists Based on Pyrimidine Scaffold As Agents for Treating Neuropathic Pain

  摘要：

  The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (sigma R-1) antagonists, associated with pharmacological antineuropathic pain activity, are the focus of this article. The new compounds were evaluated in vitro in sigma-1 and sigma-2 receptor binding assays. The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model. The most promising derivative was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (137), which exhibited a high binding affinity to sigma R-1 receptor (K-i sigma(1) = 1.06 nM) and good sigma-1/2 selectivity (1344-fold). In in vivo tests, compound 137 exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain. In addition, no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted. These data suggest compound 137 may constitute a novel class of drugs for the treatment of neuropathic pain.

  DOI：

  10.1021/jm501207r
• 作为产物：
  描述：

  4-甲氧基-6-(4-甲氧基-苄氧基)-2-苯基-嘧啶 在 三氟乙酸 、 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以83%的产率得到6-甲氧基-2-苯基-4(1H)-嘧啶酮
  参考文献：
  名称：

  WO2008/95999

  摘要：

  公开号：

文献信息

• [EN] MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA PROTÉASE DU VIRUS DE L'HÉPATITE C
  申请人：PHENOMIX CORP

  公开号：WO2010033466A1

  公开（公告）日：2010-03-25

  The invention provides macrocyclic compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically indicated, and methods of treatment of a Hepatitis C viral infection in a human patient.

  本发明提供了一种抑制丙型肝炎病毒蛋白酶的大环化合物，包括该化合物的组合物、组合物、治疗方法，在医学上有抑制丙型肝炎病毒蛋白酶的指征的条件下的治疗方法，以及治疗人类患者丙型肝炎病毒感染的方法。
• PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS
  申请人：Belfrage Anna Karin Gertrud Linnea

  公开号：US20100113440A1

  公开（公告）日：2010-05-06

  Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.

  化合物式（I）的化合物，包括其立体异构体，或N-氧化物，药学上可接受的加成盐，或药学上可接受的加成溶剂；作为HCV抑制剂有用；制备这些化合物的过程以及包含这些化合物作为活性成分的药物组合物。
• Pyrimidine substituted macrocyclic HCV inhibitors
  申请人：Raboisson Pierre Jean-Marie Bernard

  公开号：US08937080B2

  公开（公告）日：2015-01-20

  Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.

  公式为I的化合物，包括其立体异构体或N-氧化物、药学上可接受的加合盐或药学上可接受的加合溶剂；作为HCV抑制剂有用；制备这些化合物的方法以及包含这些化合物作为活性成分的制药组合物。
• US8937080B2
  申请人：——

  公开号：US8937080B2

  公开（公告）日：2015-01-20
• [EN] PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES DU VIRUS DE L'HÉPATITE C (VHC) SUBSTITUÉS PAR PYRIMIDINE
  申请人：TIBOTEC PHARM LTD

  公开号：WO2008095999A1

  公开（公告）日：2008-08-14

  [EN] Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.
  [FR] L'invention concerne des composés de formule (I) comprenant un stéréoisomère ou un N-oxyde, ou un sel d'addition pharmaceutiquement acceptable ou un solvate d'addition pharmaceutiquement acceptable. Ces composés sont utiles comme inhibiteurs du virus de l'hépatite C (VHC). L'invention concerne également des procédés de préparation de ces composés, ainsi que des compositions pharmaceutiques les comprenant et agissant comme ingrédient actif.